Article
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.
Cancer cell - 10 Oct 2022
Nassar Amin H, Adib Elio, Abou Alaiwi Sarah, El Zarif Talal, Groha Stefan, Akl Elie W, Nuzzo Pier Vitale, Mouhieddine Tarek H, Perea-Chamblee Tomin, Taraszka Kodi, El-Khoury Habib, Labban Muhieddine, Fong Christopher, Arora Kanika S, Labaki Chris, Xu Wenxin, Sonpavde Guru, Haddad Robert I, Mouw Kent W, Giannakis Marios, Hodi F Stephen, Zaitlen Noah, Schoenfeld Adam J, Schultz Nikolaus, Berger Michael F, MacConaill Laura E, Ananda Guruprasad, Kwiatkowski David J, Choueiri Toni K, Schrag Deborah, Carrot-Zhang Jian, Gusev Alexander
Abstract excerpt
The immune checkpoint inhibitor (ICI) pembrolizumab is US FDA approved for treatment of solid tumors with high tumor mutational burden (TMB-high; ≥10 variants/Mb). However, the extent to which TMB-high generalizes as an accurate biomarker in diverse patient populations is largely unknown. Using two clinical cohorts, we investigated the interplay between genetic ancestry, TMB, and tumor-only versus tumor-normal...
Topics
Join the communities discussing this publication.